Drugs / HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN
HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN
also known as
Hiberix · Tritanrix-HepB/ Hiberix · Hib · Haemophilus Influenzae Type b (Hib) vaccine · HiberixTM
Trials 9 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 22 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00323622 Comparator | Apr 2005 → May 2007 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01061541 Comparator | Aug 2003 → Jan 2004 | haemophilus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00771849 Comparator | Aug 2003 → Mar 2004 | meningitis, meningococcemia | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT03620162 Background | Oct 2018 → Dec 2020 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03621670 Background | Jul 2018 → Dec 2024 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT03207750 Background | Sep 2017 → Oct 2018 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01309646 Comparator | Mar 2011 → Feb 2012 | diphtheria, haemophilus infectious disease, poliomyelitis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01025544 Comparator | Sep → Dec 2009 | haemophilus infectious disease | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00911144 Background | Jun 2009 → Jan 2010 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00814710 Comparator | Mar → Nov 2009 | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01251133 Comparator | Jul 2008 → Mar 2009 | haemophilus infectious disease | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00680914 Background | Jun 2008 → May 2009 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00547248 Background | Oct 2007 → May 2008 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01019772 Comparator | Jul 2007 → Aug 2008 | haemophilus infectious disease | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00473668 Comparator | Jun 2007 → Jan 2008 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00344318 Background | Aug 2006 → Apr 2007 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00326118 Comparator | Jun 2006 → Nov 2007 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00332566 Comparator | Jun → Oct 2006 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00291343 Background | Feb 2006 → Mar 2007 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00317187 Comparator | Jun 2004 → Jan 2005 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00317135 Comparator | Dec 2003 → Oct 2004 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01457508 Comparator | Jan 1999 → Mar 2000 | diphtheria, hepatitis B virus infection, pertussis, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297977 ↗ |
| Known as | Haemophilus Influenzae Type b (Hib) vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00771849 ↗ |
| Known as | Hib | “Hiberix (Hib) was administered intramuscularly on Day 1, Day 61, and Day 121.” NCT03621670 ↗ |
| Known as | Hiberix | “Hib (Hiberix™) vaccine” NCT01457508 ↗25 |
| Known as | HiberixTM | “Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)” NCT00814710 ↗ |
| Known as | Tritanrix-HepB/ Hiberix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00473668 ↗ |
| Modality | Vaccine | “Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine” NCT00136604 ↗ |
| Route | Intramuscular | “intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm” NCT00136604 ↗ |